MA50609B1 - Énantiomères de thiazoles substitués utilisés comme composés antiviraux - Google Patents
Énantiomères de thiazoles substitués utilisés comme composés antivirauxInfo
- Publication number
- MA50609B1 MA50609B1 MA50609A MA50609A MA50609B1 MA 50609 B1 MA50609 B1 MA 50609B1 MA 50609 A MA50609 A MA 50609A MA 50609 A MA50609 A MA 50609A MA 50609 B1 MA50609 B1 MA 50609B1
- Authority
- MA
- Morocco
- Prior art keywords
- enantiomers
- antiviral compounds
- substituted thiazoles
- thiazoles used
- antiviral
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003557 thiazoles Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La présente invention concerne de nouveaux composés antiviraux présentant une stéréoconfiguration spécifique, plus particulièrement de nouveaux énantiomères spécifiques, un procédé pour leur préparation et leur utilisation en tant que médicaments, en particulier en tant que médicaments antiviraux.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195047 | 2017-10-05 | ||
| PCT/EP2018/077022 WO2019068817A1 (fr) | 2017-10-05 | 2018-10-04 | Énantiomères de thiazoles substitués utilisés comme composés antiviraux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50609A MA50609A (fr) | 2020-08-12 |
| MA50609B1 true MA50609B1 (fr) | 2023-03-31 |
Family
ID=60022026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50609A MA50609B1 (fr) | 2017-10-05 | 2018-10-04 | Énantiomères de thiazoles substitués utilisés comme composés antiviraux |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US11278534B2 (fr) |
| EP (2) | EP4209491A1 (fr) |
| JP (1) | JP7215689B2 (fr) |
| KR (1) | KR102708082B1 (fr) |
| CN (1) | CN111433203B (fr) |
| AR (1) | AR113344A1 (fr) |
| AU (1) | AU2018344471B2 (fr) |
| BR (1) | BR112020006710A2 (fr) |
| CA (1) | CA3077397A1 (fr) |
| CL (1) | CL2020000869A1 (fr) |
| CR (1) | CR20200154A (fr) |
| DK (1) | DK3692039T3 (fr) |
| EA (1) | EA202090620A1 (fr) |
| EC (1) | ECSP20021132A (fr) |
| ES (1) | ES2939652T3 (fr) |
| FI (1) | FI3692039T3 (fr) |
| HR (1) | HRP20230158T1 (fr) |
| HU (1) | HUE061307T2 (fr) |
| IL (1) | IL273681B1 (fr) |
| JO (1) | JOP20200110A1 (fr) |
| LT (1) | LT3692039T (fr) |
| MA (1) | MA50609B1 (fr) |
| MD (1) | MD3692039T2 (fr) |
| MX (1) | MX2020003369A (fr) |
| NI (1) | NI202000025A (fr) |
| PH (1) | PH12020550132A1 (fr) |
| PL (1) | PL3692039T3 (fr) |
| PT (1) | PT3692039T (fr) |
| RS (1) | RS64000B1 (fr) |
| SG (1) | SG11202002420SA (fr) |
| SI (1) | SI3692039T1 (fr) |
| TW (1) | TWI706941B (fr) |
| UA (1) | UA126163C2 (fr) |
| UY (1) | UY37917A (fr) |
| WO (1) | WO2019068817A1 (fr) |
| ZA (1) | ZA202002150B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061307T2 (hu) * | 2017-10-05 | 2023-06-28 | Innovative Molecules Gmbh | Szubsztituált tiazolok enantiomerei mint vírusellenes vegyületek |
| WO2019168874A1 (fr) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Compositions de difluorométhoxylation et de trifluorométhoxylation et leurs procédés de synthèse |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| CN116783171A (zh) | 2020-10-29 | 2023-09-19 | 创新分子股份有限公司 | 作为抗病毒化合物的氘化氨基噻唑化合物 |
| IL314188A (en) | 2022-01-17 | 2024-09-01 | Innovative Molecules Gmbh | Solid crystalline forms of helicase-primase inhibitors and a process for their preparation |
| WO2024047508A1 (fr) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Compositions pharmaceutiques contre le virus de l'herpès |
| WO2024049760A1 (fr) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Composés de thiazolyl-urée cyclique pour le traitement du vhs |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA984848A (en) | 1970-01-16 | 1976-03-02 | Kurt H. Pilgram | Herbicides |
| SK89398A3 (en) | 1995-12-29 | 1998-11-04 | Boehringer Ingelheim Pharma | Phenyl thiazole derivatives with anti herpes virus properties |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| ES2189404T3 (es) | 1998-03-19 | 2003-07-01 | Upjohn Co | 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv. |
| US6500817B1 (en) | 1999-03-08 | 2002-12-31 | Bayer Aktiengesellschaft | Thiazolyl urea derivatives and their utilization as antiviral agents |
| DE19959958A1 (de) | 1999-12-13 | 2001-08-30 | Bayer Ag | Thiazolylharnstoff-Derivate |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| DE10039265A1 (de) | 2000-08-11 | 2002-02-21 | Bayer Ag | Thiazolylamid-Derivate |
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| CA2412720A1 (fr) | 2000-06-15 | 2001-12-20 | Bayer Aktiengesellschaft | Methodes d'identification de composes presentant une activite antiherpes |
| DE10038022A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Inverse Thiazolylamid-Derivate |
| DE10044353A1 (de) | 2000-09-07 | 2002-04-04 | Bayer Ag | Unkompetitive Inhibitoren der Helikase-Primase |
| DE10044358A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonylheterocyclyl-Derivate |
| DE10044328A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10129716A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129717A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129715A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Thiazolylamide |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| DE10210319A1 (de) | 2002-03-08 | 2003-09-18 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10235967B4 (de) | 2002-08-06 | 2005-09-08 | Bayer Healthcare Ag | Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung |
| DE10300109A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Methode zur Inhibition der Replikation von Herpesviren |
| BRPI0507278A (pt) | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| EP2101640B1 (fr) | 2006-12-08 | 2013-05-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Casquette d'électrodes sèches pour électoro-encéphalographie |
| DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| EP2635124A4 (fr) * | 2010-11-01 | 2014-04-16 | Romark Lab Lc | Composés thiazolide substitués par un groupe alkylsulfinyle |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2573086A1 (fr) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | Monohydrate de mesylate acétamide N-[5-(Aminosulfonyl)-4-méthyl-1,3-thiazol-2-yl]-N-méthyl-2-[4-(2-pyridinyl)phényl] |
| AU2017245679B2 (en) * | 2016-04-06 | 2021-07-01 | Innovative Molecules Gmbh | Aminothiazole derivatives useful as antiviral agents |
| UY37496A (es) | 2016-11-28 | 2018-06-29 | Aicuris Anti Infective Cures Gmbh | Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo |
| HUE054845T2 (hu) | 2016-11-28 | 2021-10-28 | Aicuris Gmbh & Co Kg | Az N-[5-(amino-szulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamid szabad bázis maleát sója, gyógyászati készítmények, elõállítási eljárások és Herpes vírusok kezelésére történõ alkalmazások |
| WO2018095576A1 (fr) | 2016-11-28 | 2018-05-31 | Aicuris Anti-Infective Cures Gmbh | Formulation pharmaceutique topique comprenant du n-[5-(aminosulfonyle)-4-méthyl-1,3-thiazol-2-yl]-n-méthyl-2-[4-(2-pyridinyl)-phényl]-acétamide |
| JP7150343B2 (ja) | 2017-01-09 | 2022-10-11 | フェーノ・セラピューティクス・カンパニー・リミテッド | チアゾール誘導体およびその使用 |
| HUE061307T2 (hu) * | 2017-10-05 | 2023-06-28 | Innovative Molecules Gmbh | Szubsztituált tiazolok enantiomerei mint vírusellenes vegyületek |
-
2018
- 2018-10-04 HU HUE18779696A patent/HUE061307T2/hu unknown
- 2018-10-04 IL IL273681A patent/IL273681B1/en unknown
- 2018-10-04 MX MX2020003369A patent/MX2020003369A/es unknown
- 2018-10-04 SI SI201830861T patent/SI3692039T1/sl unknown
- 2018-10-04 FI FIEP18779696.6T patent/FI3692039T3/fi active
- 2018-10-04 PT PT187796966T patent/PT3692039T/pt unknown
- 2018-10-04 MD MDE20200816T patent/MD3692039T2/ro unknown
- 2018-10-04 UY UY0001037917A patent/UY37917A/es unknown
- 2018-10-04 MA MA50609A patent/MA50609B1/fr unknown
- 2018-10-04 EA EA202090620A patent/EA202090620A1/ru unknown
- 2018-10-04 SG SG11202002420SA patent/SG11202002420SA/en unknown
- 2018-10-04 PL PL18779696.6T patent/PL3692039T3/pl unknown
- 2018-10-04 DK DK18779696.6T patent/DK3692039T3/da active
- 2018-10-04 RS RS20230156A patent/RS64000B1/sr unknown
- 2018-10-04 LT LTEPPCT/EP2018/077022T patent/LT3692039T/lt unknown
- 2018-10-04 WO PCT/EP2018/077022 patent/WO2019068817A1/fr active Application Filing
- 2018-10-04 HR HRP20230158TT patent/HRP20230158T1/hr unknown
- 2018-10-04 BR BR112020006710A patent/BR112020006710A2/pt unknown
- 2018-10-04 EP EP22213253.2A patent/EP4209491A1/fr active Pending
- 2018-10-04 JP JP2020519403A patent/JP7215689B2/ja active Active
- 2018-10-04 JO JOP/2020/0110A patent/JOP20200110A1/ar unknown
- 2018-10-04 TW TW107135101A patent/TWI706941B/zh active
- 2018-10-04 EP EP18779696.6A patent/EP3692039B1/fr active Active
- 2018-10-04 AU AU2018344471A patent/AU2018344471B2/en active Active
- 2018-10-04 ES ES18779696T patent/ES2939652T3/es active Active
- 2018-10-04 CA CA3077397A patent/CA3077397A1/fr active Pending
- 2018-10-04 CR CR20200154A patent/CR20200154A/es unknown
- 2018-10-04 KR KR1020207009294A patent/KR102708082B1/ko active IP Right Grant
- 2018-10-04 US US16/753,814 patent/US11278534B2/en active Active
- 2018-10-04 UA UAA202002635A patent/UA126163C2/uk unknown
- 2018-10-04 CN CN201880065255.2A patent/CN111433203B/zh active Active
- 2018-10-04 AR ARP180102864A patent/AR113344A1/es unknown
-
2020
- 2020-03-25 PH PH12020550132A patent/PH12020550132A1/en unknown
- 2020-04-01 CL CL2020000869A patent/CL2020000869A1/es unknown
- 2020-04-01 NI NI202000025A patent/NI202000025A/es unknown
- 2020-04-03 EC ECSENADI202021132A patent/ECSP20021132A/es unknown
- 2020-05-04 ZA ZA2020/02150A patent/ZA202002150B/en unknown
-
2022
- 2022-01-21 US US17/581,166 patent/US20220152008A1/en active Pending
-
2024
- 2024-06-06 US US18/736,166 patent/US20240316021A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50609B1 (fr) | Énantiomères de thiazoles substitués utilisés comme composés antiviraux | |
| MA46325B1 (fr) | Composés dinucléotidiques cycliques | |
| MA49809A1 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
| CU20180073A7 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| MX2022016427A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| FR3068979B1 (fr) | Composition d'adhesif (meth)acrylique, son procede de preparation et son utilisation | |
| BR112018071511A2 (pt) | polímeros à base de etileno e processos para fazer os mesmos | |
| BR112017017349A2 (pt) | composto, composição, método para tratar um distúrbio | |
| MA40895B1 (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| PE20221420A1 (es) | Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
| MA50895A (fr) | Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
| MX2019004182A (es) | Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al. | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MA39387A1 (fr) | Colorants réactifs fluorescents, procédé de production et utilisation de ceux-ci | |
| MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
| FR3062851B1 (fr) | Procede de preparation monotope de composes organo-iodes | |
| FR3019549B1 (fr) | Composition de poudre de polymere a etapes multiples, son procede de preparation et son utilisation | |
| EA202092707A1 (ru) | Огнеупор, шихта для его получения, способ его получения, а также применение такого огнеупора | |
| MX2024008108A (es) | Compuesto especifico de receptor wnt y metodo relacionado con este. | |
| MA43158B1 (fr) | Composés oxa-diazadispiro possédant une activité contre la douleur |